Jazz Pharma legal chief sells 1,192 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported an open-market sale of 1,192 Ordinary Shares at $236.97 per share. After this transaction, she directly holds 52,626 shares.
The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026, indicating it was pre-scheduled rather than a discretionary trade based on short-term market conditions.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 1,192 | $236.97 | $282K |
Footnotes (1)
- F1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Key Figures
Key Terms
Rule 10b5-1 regulatory
open-market sale financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Neena M. Patil?
What is the significance of Rule 10b5-1 in the Jazz Pharmaceuticals (JAZZ) insider sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.